Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 4/20 | 0.85 |
| ▸ | LMNA | P02545 | 2/20 | 0.75 |
| ▸ | HTT | P42858 | 2/20 | 0.75 |
| ▸ | ACLY | P53396 | 1/20 | 0.72 |
| ▸ | TP53 | P04637 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | CCR9 | P51686 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7409073 | 0.99 | METAP2 (0.82) | METAP2LMNAHTTACLYTP53 | |
| SCHEMBL491833 | 0.92 | METAP2 (1.00) | METAP2LMNAHTTACLYTP53 | |
| SCHEMBL492024 | 0.91 | ACLY (0.81) | METAP2ACLY | |
| SCHEMBL7409071 | 0.89 | LMNA (0.71) | METAP2LMNAHTTACLYTP53 | |
| SCHEMBL12570805 | 0.88 | METAP2 (0.86) | METAP2LMNAHTTACLYCYP1A2 | |
| SCHEMBL1139356 | 0.87 | ACLY (0.78) | METAP2LMNAHTTACLY | |
| SCHEMBL1291344 | 0.86 | LMNA (0.68) | METAP2LMNAHTTACLYTP53 | |
| SCHEMBL11182634 | 0.86 | LMNA (1.00) | METAP2LMNAHTTTP53MAPT | |
| SCHEMBL16496289 | 0.86 | METAP2 (0.75) | METAP2LMNAHTTACLYCYP1A2 | |
| SCHEMBL10249221 | 0.85 | ACLY (0.67) | METAP2LMNAACLYCCR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1385820-B1 | ANTHRANILIC ACID AMIDES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS ANTIARRHYTHMIA AGENTS, AND PHARMACEUTICAL PREPARATIONS THEREOF | SANOFI AVENTIS DEUTSCHLAND (DE) | 2011-10-12 | — | — | EP | disclosed |
| US-7332608-B2 | Anthranilamides and methods of their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-02-19 | — | — | US | disclosed |
| US-7332608-B2 | Anthranilamides and methods of their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-02-19 | — | — | US | disclosed |
| US-7235690-B2 | Anthranilamides and methods of their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-26 | — | — | US | disclosed |
| US-7235690-B2 | Anthranilamides and methods of their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-26 | — | — | US | disclosed |
| US-20070117807-A1 | ANTHRANILAMIDES AND METHODS OF THEIR USE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-05-24 | — | — | US | disclosed |
| US-20070117807-A1 | ANTHRANILAMIDES AND METHODS OF THEIR USE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-05-24 | — | — | US | disclosed |
| EP-0354994-B1 | Quinoline derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1995-01-25 | — | — | EP | disclosed |
| US-5254565-A | Enzyme inhibitors; anticholesterol agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-10-19 | — | — | US | disclosed |
| EP-0354994-A2 | Quinoline derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1990-02-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117807-A1 | ANTHRANILAMIDES AND METHODS OF THEIR USE | KCNH1, KCNH2, KCNJ2 | METAP2 4099/4885LMNA 981/4885HTT 4289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.